Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,529 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety.
Sugitani I, Ueda S, Sakurai T, Shigekawa T, Hirokawa E, Shimada H, Takeuchi H, Matsuura K, Misumi M, Fujiuchi N, Takahashi T, Hasebe T, Osaki A, Saeki T. Sugitani I, et al. Among authors: sakurai t. Int J Clin Oncol. 2017 Oct;22(5):880-886. doi: 10.1007/s10147-017-1136-8. Epub 2017 May 25. Int J Clin Oncol. 2017. PMID: 28547525 Free PMC article. Clinical Trial.
A Real-World Retrospective Cohort Study of Combined Therapy with Bevacizumab and Paclitaxel in Japanese Patients with Metastatic Breast Cancer.
Yamada H, Inoue K, Nagai SE, Nakai M, Arisawa F, Ueda H, Saito T, Ninomiya J, Kuroda T, Sakurai T, Kodama H, Kimizuka K, Hata S, Kai T, Kurosumi M; SBCCSG investigators. Yamada H, et al. Among authors: sakurai t. J Nippon Med Sch. 2017;84(5):215-223. doi: 10.1272/jnms.84.215. J Nippon Med Sch. 2017. PMID: 29142182 Free article.
TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study.
Inoue K, Nagai SE, Saito T, Sakurai T, Kimizuka K, Yamada H, Kuroda T, Hata S, Yamazaki Y, Kojima M, Futsuhara K; SBCCSG-14 investigators. Inoue K, et al. Among authors: sakurai t. Invest New Drugs. 2020 Feb;38(1):140-147. doi: 10.1007/s10637-019-00829-w. Epub 2019 Jul 10. Invest New Drugs. 2020. PMID: 31289984 Free PMC article.
Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study).
Kimizuka K, Inoue K, E Nagai S, Saito T, Nakano S, Futsuhara K, Yamada H, Kaneko S, Sakurai T, Hata S, Kurosumi M. Kimizuka K, et al. Among authors: sakurai t. J Nippon Med Sch. 2019;86(3):165-171. doi: 10.1272/jnms.JNMS.2019_86-305. J Nippon Med Sch. 2019. PMID: 31292328 Free article.
Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
Inoue K, Saito T, Okubo K, Kimizuka K, Yamada H, Sakurai T, Ishizuna K, Hata S, Kai T, Kurosumi M. Inoue K, et al. Among authors: sakurai t. Breast Cancer Res Treat. 2016 Jun;157(2):295-305. doi: 10.1007/s10549-016-3808-x. Epub 2016 Apr 28. Breast Cancer Res Treat. 2016. PMID: 27125669 Free PMC article. Clinical Trial.
Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
Hayashida T, Jinno H, Mori K, Sato H, Matsui A, Sakurai T, Hattori H, Takayama S, Wada M, Takahashi M, Seki H, Seki T, Nagayama A, Matsumoto A, Kitagawa Y. Hayashida T, et al. Among authors: sakurai t. BMC Cancer. 2018 Jun 28;18(1):701. doi: 10.1186/s12885-018-4628-7. BMC Cancer. 2018. PMID: 29954362 Free PMC article. Clinical Trial.
3,529 results